Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1701673 | 0.74 | MAP4K4 (0.30) | — | |
| SCHEMBL27404245 | 0.69 | CYP1A2 (0.47) | CYP1A2POLBCYP2D6CYP2C9 | |
| SCHEMBL23589214 | 0.68 | EGFR (0.37) | CYP1A2POLBCYP2D6CYP2C9 | |
| SCHEMBL1701973 | 0.67 | AXL (0.32) | — | |
| SCHEMBL12156330 | 0.65 | NPC1 (0.34) | CYP1A2POLBCYP2D6CYP2C9 | |
| SCHEMBL1701957 | 0.65 | SLC6A2 (0.33) | CYP1A2POLBCYP2D6CYP2C9 | |
| SCHEMBL24566578 | 0.65 | PTPN1 (0.33) | — | |
| SCHEMBL26844080 | 0.64 | JAK2 (0.30) | — | |
| SCHEMBL24393074 | 0.64 | EGFR (0.40) | CYP1A2POLBCYP2D6CYP2C9 | |
| SCHEMBL22054405 | 0.64 | PIK3C3 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | CALCIMEDICA, INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263612-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | CYP1A2 4570/4885POLB 4774/4885CYP2D6 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.